Contract analysis

1. Purpose and Signing Confirmation We are pleased to confirm that all principal transaction documents in connection with the $15,000,000 senior secured bridge credit facility (the "Bridge Loan") were duly executed and delivered by all parties on today's date, March 6, 2026 (the "Signing Date"). This letter summarizes the documents that were executed, identifies the conditions precedent to funding that remain outstan

2. Summary of Executed Transaction Documents The following transaction documents were executed by all applicable parties on the Signing Date. Unless otherwise indicated, each document is dated as of March 6, 2026:

1. Bridge Loan Agreement. Senior Secured Bridge Credit Agreement dated March 6, 2026, among GenomeDx (as Borrower), Pinnacle (as Administrative Agent and a Lender), Cobalt (as a Lender), and PFS (as Collateral Agent). The Bridge Loan Agreement sets forth the terms and conditions of the $15,000,000 facility, including the interest rate, maturity, repayment provisions, representations and warranties, affirmative and ne

2. Security Agreement. Security Agreement dated March 6, 2026, between GenomeDx (as Grantor) and PFS (as Collateral Agent), pursuant to which GenomeDx has granted a first-priority security interest in substantially all of its assets in favor of the Collateral Agent for the ratable benefit of the Lenders. The security interest is subject to the intercreditor arrangement with Ridgeline Capital Partners LLC ("Ridgeline"

3. IP Security Agreement. Short-form Patent and Trademark Security Agreement dated March 6, 2026, between GenomeDx and PFS, prepared in recordable form for filing with the United States Patent and Trademark Office (the "USPTO"). This agreement covers GenomeDx's intellectual property portfolio, which currently comprises 14 issued U.S. patents and 7 pending PCT applications, as set forth in the schedules attached there

4. Warrant Agreement — Pinnacle. Common Stock Purchase Warrant dated March 6, 2026, issued by GenomeDx to Pinnacle for the purchase of 137,614 shares of GenomeDx common stock, par value $0.001 per share. The per-share exercise price is equal to the lesser of (a) $2.18 and (b) 80% of the price per share paid by investors in GenomeDx's anticipated Series C preferred stock financing (the "Series C"). The warrant has a t

5. Warrant Agreement — Cobalt. Common Stock Purchase Warrant dated March 6, 2026, issued by GenomeDx to Cobalt for the purchase of 68,807 shares of GenomeDx common stock, par value $0.001 per share, on terms substantially identical to the Pinnacle warrant, including with respect to exercise price and 10-year term.

6. Intercreditor Agreement. Intercreditor Agreement dated March 6, 2026, among Pinnacle (in its capacity as Administrative Agent for the bridge Lenders), Ridgeline, and GenomeDx, with acknowledgment by PFS (as Collateral Agent). The Intercreditor Agreement establishes the relative lien priority between the bridge Lenders and Ridgeline with respect to two categories of collateral: (a) "Ridgeline Priority Collateral,"

3. Remaining Conditions Precedent to Funding Funding of the Bridge Loan remains subject to the satisfaction (or waiver by the Lenders) of certain conditions precedent set forth in Article V of the Bridge Loan Agreement. Below is a summary of the deliverables that remain outstanding as of the Signing Date and must be satisfied on or prior to the anticipated Funding Date of March 13, 2026. We have included the current

4. Anticipated Funding Timeline Set forth below is a summary of the anticipated timeline from the Signing Date through the Funding Date. We ask that GenomeDx personnel treat the target dates below as firm deadlines in order to ensure that closing occurs on March 13, 2026, as currently anticipated. We note that the first interest payment under the Bridge Loan Agreement will be due on April 1, 2026, reflecting interest

5. Action Items for GenomeDx For ease of reference, we have summarized below the immediate action items requiring attention from GenomeDx personnel. We ask that these items be addressed promptly to ensure that all conditions precedent to funding are satisfied by the target dates set forth in the timeline above.

1. Miriam Sato (General Counsel and Secretary): • Review, finalize, and execute the Officer's Certificate (Secretary's Certificate), including verification of the attached board resolutions, certificate of incorporation, bylaws, and incumbency certificates for Dr. Mehta and Rob Langford. Please advise us of any comments on the draft circulated on March 4 at your earliest convenience. • Coordinate with GenomeDx's insu

2. Robert "Rob" Langford (Chief Financial Officer): • Order expedited certificates of good standing from both the Delaware Secretary of State and the California Secretary of State. Please submit orders no later than March 9, 2026 to ensure timely receipt. GenomeDx's Delaware registered agent (National Registered Agents of Delaware Inc., 1209 Orange Street, Wilmington, DE 19801) may be able to assist with expedited pr

3. Dr. Ananya Mehta (Chief Executive Officer and Co-Founder): • No specific action items at this time. We will keep Dr. Mehta informed of the funding timeline and will notify her promptly if any issues arise that require her attention.

6. Post-Closing Reminders We want to take this opportunity to briefly highlight certain ongoing obligations of GenomeDx under the Bridge Loan Agreement that will become effective upon funding. Calderwood & Harkness will prepare a comprehensive post-closing compliance calendar and circulate it to Miriam and Rob promptly following the Closing Date, but in the interim, we draw your attention to the following key items:

7. Closing We are very pleased with the successful execution of all transaction documents on today's date and look forward to working with you and the GenomeDx team to complete the remaining closing deliverables and achieve funding on March 13, 2026. The Bridge Loan represents an important milestone for GenomeDx as the company continues to advance its pipeline and prepare for the anticipated Series C financing, and w